the effect that the reverse stock split may have on the price of the Company's common stock; the ability or inability to maintain the listing of Conduit's securities on Nasdaq; the ability to ...

the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of Conduit’s securities on Nasdaq; the ability to ...

23, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc ... its board of directors has approved a 1-for-100 reverse stock split of the Company’s common stock. The Company’s stockholders ...

(Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, announces that its board of ...

(Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound ...

(Nasdaq: CDT) ("Conduit” or the "Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, announces that its board of ...

(RTTNews) - Conduit Pharmaceuticals Inc. (CDT), a life science company, Thursday, announced that its board of directors has approved a 1-for-100 reverse stock split of the company's common stock.

In response, stockholders approved a reverse stock split to meet Nasdaq's requirements. The company also appointed Simon Fry as a new director and amended its bylaws. In addition, Conduit ...

NAPLES, Fla. and CAMBRIDGE, United Kingdom (TADAWUL:4280) - Conduit Pharmaceuticals Inc. (NASDAQ:CDT), a clinical stage life science company with a current market capitalization of $7.49 million, ...